TY - JOUR
T1 - Detection and localization of surgically resectable cancers with a multi-analyte blood test
AU - Cohen, Joshua D.
AU - Li, Lu
AU - Wang, Yuxuan
AU - Thoburn, Christopher
AU - Afsari, Bahman
AU - Danilova, Ludmila
AU - Douville, Christopher
AU - Javed, Ammar A.
AU - Wong, Fay
AU - Mattox, Austin
AU - Hruban, Ralph H.
AU - Wolfgang, Christopher L.
AU - Goggins, Michael G.
AU - Molin, Marco Dal
AU - Wang, Tian Li
AU - Roden, Richard
AU - Klein, Alison P.
AU - Ptak, Janine
AU - Dobbyn, Lisa
AU - Schaefer, Joy
AU - Silliman, Natalie
AU - Popoli, Maria
AU - Vogelstein, Joshua T.
AU - Browne, James D.
AU - Schoen, Robert E.
AU - Brand, Randall E.
AU - Tie, Jeanne
AU - Gibbs, Peter
AU - Wong, Hui Li
AU - Mansfield, Aaron S.
AU - Jen, Jin
AU - Hanash, Samir M.
AU - Falconi, Massimo
AU - Allen, Peter J.
AU - Zhou, Shibin
AU - Bettegowda, Chetan
AU - Diaz, Luis A.
AU - Tomasetti, Cristian
AU - Kinzler, Kenneth W.
AU - Vogelstein, Bert
AU - Lennon, Anne Marie
AU - Papadopoulos, Nickolas
N1 - Publisher Copyright:
© 2017 The Authors.
PY - 2018/2/23
Y1 - 2018/2/23
N2 - Earlier detection is key to reducing cancer deaths. Here, we describe a blood test that can detect eight common cancer types through assessment of the levels of circulating proteins and mutations in cell-free DNA. We applied this test, called CancerSEEK, to 1005 patients with nonmetastatic, clinically detected cancers of the ovary, liver, stomach, pancreas, esophagus, colorectum, lung, or breast. CancerSEEK tests were positive in a median of 70% of the eight cancer types. The sensitivities ranged from 69 to 98% for the detection of five cancer types (ovary, liver, stomach, pancreas, and esophagus) for which there are no screening tests available for average-risk individuals. The specificity of CancerSEEK was greater than 99%: only 7 of 812 healthy controls scored positive. In addition, CancerSEEK localized the cancer to a small number of anatomic sites in a median of 83% of the patients.
AB - Earlier detection is key to reducing cancer deaths. Here, we describe a blood test that can detect eight common cancer types through assessment of the levels of circulating proteins and mutations in cell-free DNA. We applied this test, called CancerSEEK, to 1005 patients with nonmetastatic, clinically detected cancers of the ovary, liver, stomach, pancreas, esophagus, colorectum, lung, or breast. CancerSEEK tests were positive in a median of 70% of the eight cancer types. The sensitivities ranged from 69 to 98% for the detection of five cancer types (ovary, liver, stomach, pancreas, and esophagus) for which there are no screening tests available for average-risk individuals. The specificity of CancerSEEK was greater than 99%: only 7 of 812 healthy controls scored positive. In addition, CancerSEEK localized the cancer to a small number of anatomic sites in a median of 83% of the patients.
UR - http://www.scopus.com/inward/record.url?scp=85040865768&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85040865768&partnerID=8YFLogxK
U2 - 10.1126/science.aar3247
DO - 10.1126/science.aar3247
M3 - Article
C2 - 29348365
AN - SCOPUS:85040865768
SN - 0036-8075
VL - 359
SP - 926
EP - 930
JO - Science
JF - Science
IS - 6378
ER -